Literature DB >> 19594737

Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times.

Michael M Lieber1, Thomas Rhodes, Debra J Jacobson, Michaela E McGree, Cynthia J Girman, Steven J Jacobsen, Jennifer L St Sauver.   

Abstract

OBJECTIVES: To measure prostate volume doubling times (PVDTs) for a large sample of community men followed serially by transrectal ultrasonography (TRUS), and to determine whether specific characteristics are associated with a rapid PVDT. SUBJECTS AND METHODS: A subsample of 446 subjects from a larger cohort of American white men aged 40-79 years were evaluated biennially for a median (range) follow-up of 10 (3-14) years. Mixed-effects regression models were used to estimate prostate growth rates and PVDT for subjects with three or more or with five or more serial biennial TRUS PV measurements.
RESULTS: The median (25-75th percentile) PVDT was 32.6 (24.6-44.0) years. The average annual increase in PV was 2.2%. The PVDT distribution was constant in men of all age groups studied (r < 0.001, P = 0.99). The factor most strongly associated with PVDT was baseline transition zone volume (r = -0.55, P < 0.001). Baseline total prostate-specific antigen (PSA) level, free PSA and total PV were also significantly inversely associated with PVDT (r = -0.30, -0.44 and -0.32, respectively, all P < 0.001). Age, baseline anthropomorphic measurements, hormone levels and specific lifestyle characteristics were not significantly correlated with PVDT.
CONCLUSION: These data indicate that PVDT might be a useful future measure of benign prostatic growth. They provide a basis to forecast PV at 10, 20, or 30 years later, after one baseline TRUS measurement of prostate volume, and can be presented in a simple nomogram.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19594737      PMCID: PMC2862564          DOI: 10.1111/j.1464-410X.2009.08719.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Validation of a new quality of life questionnaire for benign prostatic hyperplasia.

Authors:  R S Epstein; P A Deverka; C G Chute; L Panser; J E Oesterling; M M Lieber; S Schwartz; D Patrick
Journal:  J Clin Epidemiol       Date:  1992-12       Impact factor: 6.437

2.  The Longue Durée of genetic ancestry: multiple genetic marker systems and Celtic origins on the Atlantic facade of Europe.

Authors:  Brian McEvoy; Martin Richards; Peter Forster; Daniel G Bradley
Journal:  Am J Hum Genet       Date:  2004-08-12       Impact factor: 11.025

3.  Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study.

Authors:  Arvind P Ganpule; Mahesh R Desai; Mihir M Desai; Kishor D Wani; Sharad D Bapat
Journal:  BJU Int       Date:  2004-08       Impact factor: 5.588

4.  Parameters of prostate volume and shape in a community based population of men 55 to 74 years old.

Authors:  J L Bosch; W C Hop; A Q Niemer; C H Bangma; W J Kirkels; F H Schröder
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

5.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

6.  Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms.

Authors:  S J Jacobsen; C J Girman; H A Guess; L A Panser; C G Chute; J E Oesterling; M M Lieber
Journal:  Urology       Date:  1993-12       Impact factor: 2.649

7.  The natural history of prostatism: the effects of non-response bias.

Authors:  L A Panser; C G Chute; H A Guess; J J Larsonkeller; C J Girman; J E Oesterling; M M Lieber; S J Jacobsen
Journal:  Int J Epidemiol       Date:  1994-12       Impact factor: 7.196

8.  New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States.

Authors:  S J Jacobsen; C J Girman; H A Guess; J E Oesterling; M M Lieber
Journal:  Arch Intern Med       Date:  1995-03-13

9.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

10.  Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men?

Authors:  S J Jacobsen; C J Girman; H A Guess; L A Panser; C G Chute; J E Oesterling; M M Lieber
Journal:  Urology       Date:  1995-01       Impact factor: 2.649

View more
  9 in total

1.  Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.

Authors:  Thomas Rhodes; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Cynthia J Girman; Michael M Lieber; George G Klee; Kitaw Demissie; Steven J Jacobsen
Journal:  Urology       Date:  2012-03       Impact factor: 2.649

Review 2.  Landmarks in BPH--from aetiology to medical and surgical management.

Authors:  Arman Kahokehr; Peter J Gilling
Journal:  Nat Rev Urol       Date:  2014-01-21       Impact factor: 14.432

3.  Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; George G Klee; Michael M Lieber; Steven J Jacobsen
Journal:  Am J Epidemiol       Date:  2011-03-02       Impact factor: 4.897

4.  Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome.

Authors:  Guillermo Lorenzo; Víctor M Pérez-García; Alfonso Mariño; Luis A Pérez-Romasanta; Alessandro Reali; Hector Gomez
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

Review 5.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

6.  Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.

Authors:  Guillermo Lorenzo; Thomas J R Hughes; Pablo Dominguez-Frojan; Alessandro Reali; Hector Gomez
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-07       Impact factor: 11.205

7.  Transurethral resection of the prostate provides more favorable clinical outcomes compared with conservative medical treatment in patients with urinary retention caused by benign prostatic obstruction.

Authors:  Yu-Hsiang Lin; Chen-Pang Hou; Tien-Hsing Chen; Horng-Heng Juang; Phei-Lang Chang; Pei-Shan Yang; Chien-Lun Chen; Ke-Hung Tsui
Journal:  BMC Geriatr       Date:  2018-01-16       Impact factor: 3.921

8.  Can men with prostates sized 80 mL or larger be managed conservatively?

Authors:  Alvin Lee; Han Jie Lee; Keong Tatt Foo
Journal:  Investig Clin Urol       Date:  2017-08-04

9.  Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada.

Authors:  Rano Matta; Erind Dvorani; Christopher Wallis; Amanda Hird; Joseph LaBossiere; Girish Kulkarni; Ronald Kodama; Lesley Carr; Sidney B Radomski; Refik Saskin; Sender Herschorn; Robert K Nam
Journal:  BMJ Open       Date:  2019-12-30       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.